Cost of Bladder Cancer in Lebanon Before and After the Economic Collapse: a Probabilistic Modeling Study

Overview

Journal Int J Equity Health

Publisher Biomed Central

Specialties Health Services
Public Health

Date 2023 May 2

PMID 37131206

Authors

Elie Raad

Samar Helou

Karl Hage

Melissa Daou

Elie El Helou

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Lebanon has one of the highest incidence rates of bladder cancer (BC) in the world. In 2019, Lebanon's economy collapsed which majorly impacted healthcare costs and coverage. This study assesses the overall direct costs of urothelial BC in Lebanon, from the perspective of public and private third-party payers (TPP) and households, and evaluates the impact of the economic collapse on these costs.

Methods: This was a quantitative, incidence-based cost-of-illness study, conducted using a macro-costing approach. Costs of medical procedures were obtained from the records of various TPPs and the Ministry of Public Health. We modeled the clinical management processes for each stage of BC, and conducted probabilistic sensitivity analyses to estimate and compare the cost of each stage, pre-and post-collapse, and for each payer category.

Results: Before the collapse, the total annual cost of BC in Lebanon was estimated at LBP 19,676,494,000 (USD 13,117,662). Post-collapse, the total annual cost of BC in Lebanon increased by 768% and was estimated at LBP 170,727,187,000 (USD 7,422,921). TPP payments increased by 61% whereas out-of-pocket (OOP) payments increased by 2,745% resulting in a decrease in TPP coverage to only 17% of total costs.

Conclusion: Our study shows that BC in Lebanon constitutes a significant economic burden costing 0.32% of total health expenditures. The economic collapse induced an increase of 768% in the total annual cost, and a catastrophic increase in OOP payments.

References

Hollenbeck B, Dunn R, Ye Z, Hollingsworth J, Skolarus T, Kim S . Delays in diagnosis and bladder cancer mortality. Cancer. 2010; 116(22):5235-42. DOI: 10.1002/cncr.25310. View

Bloom B, de Pouvourville N, Straus W . Cost of illness of Alzheimer's disease: how useful are current estimates?. Gerontologist. 2003; 43(2):158-64. DOI: 10.1093/geront/43.2.158. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Devi S . Economic crisis hits Lebanese health care. Lancet. 2020; 395(10224):548. DOI: 10.1016/S0140-6736(20)30407-4. View

Lakkis N, Adib S, Hamadeh G, El-Jarrah R, Osman M . Bladder Cancer in Lebanon: Incidence and Comparison to Regional and Western Countries. Cancer Control. 2018; 25(1):1073274818789359. PMC: 6055109. DOI: 10.1177/1073274818789359. View

Millan-Rodriguez F, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J . Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000; 164(3 Pt 1):680-4. DOI: 10.1016/s0022-5347(05)67280-1. View

Niederberger M, Spranger J . Delphi Technique in Health Sciences: A Map. Front Public Health. 2020; 8:457. PMC: 7536299. DOI: 10.3389/fpubh.2020.00457. View

Sievert K, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M . Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol. 2009; 27(3):295-300. PMC: 2694315. DOI: 10.1007/s00345-009-0395-z. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

James N, Hussain S, Hall E, Jenkins P, Tremlett J, Rawlings C . Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012; 366(16):1477-88. DOI: 10.1056/NEJMoa1106106. View

11.

Martini A, Sfakianos J, Renstrom-Koskela L, Mortezavi A, Falagario U, Egevad L . The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2019; 125(2):270-275. DOI: 10.1111/bju.14872. View

12.

Mariotto A, Yabroff K, Shao Y, Feuer E, Brown M . Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103(2):117-28. PMC: 3107566. DOI: 10.1093/jnci/djq495. View

13.

Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A . Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007; 52(1):134-41. DOI: 10.1016/j.eururo.2006.12.029. View

14.

De Villiers M, de Villiers P, Kent A . The Delphi technique in health sciences education research. Med Teach. 2005; 27(7):639-43. DOI: 10.1080/13611260500069947. View

15.

Donsky H, Coyle S, Scosyrev E, Messing E . Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urol Oncol. 2013; 32(1):40.e23-31. DOI: 10.1016/j.urolonc.2013.04.010. View

16.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

17.

Byford S, Torgerson D, Raftery J . Economic note: cost of illness studies. BMJ. 2000; 320(7245):1335. PMC: 1127320. DOI: 10.1136/bmj.320.7245.1335. View

18.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

19.

Balar A, Castellano D, ODonnell P, Grivas P, Vuky J, Powles T . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11):1483-1492. DOI: 10.1016/S1470-2045(17)30616-2. View

20.

von der Maase H, Sengelov L, Roberts J, Ricci S, Dogliotti L, Oliver T . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23(21):4602-8. DOI: 10.1200/JCO.2005.07.757. View